NO2933252T3 - - Google Patents

Info

Publication number
NO2933252T3
NO2933252T3 NO15151030A NO15151030A NO2933252T3 NO 2933252 T3 NO2933252 T3 NO 2933252T3 NO 15151030 A NO15151030 A NO 15151030A NO 15151030 A NO15151030 A NO 15151030A NO 2933252 T3 NO2933252 T3 NO 2933252T3
Authority
NO
Norway
Application number
NO15151030A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2933252T3 publication Critical patent/NO2933252T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
NO15151030A 2009-07-13 2010-07-12 NO2933252T3 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22507609P 2009-07-13 2009-07-13
US22507909P 2009-07-13 2009-07-13
US28926309P 2009-12-22 2009-12-22
EP10733116.7A EP2454250B1 (en) 2009-07-13 2010-07-12 Apoptosis signal-regulating kinase inhibitors

Publications (1)

Publication Number Publication Date
NO2933252T3 true NO2933252T3 (no) 2018-06-02

Family

ID=42670422

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15151030A NO2933252T3 (no) 2009-07-13 2010-07-12

Country Status (28)

Country Link
US (7) US8378108B2 (no)
EP (4) EP2933252B1 (no)
JP (4) JP5745721B2 (no)
KR (3) KR20170081722A (no)
CN (1) CN102482257B (no)
AR (1) AR077564A1 (no)
AU (1) AU2010273597B2 (no)
BR (1) BR112012000894A2 (no)
CA (1) CA2767894C (no)
CY (1) CY1119889T1 (no)
DK (2) DK2933252T3 (no)
ES (3) ES2533796T3 (no)
HK (2) HK1170482A1 (no)
HR (2) HRP20150185T1 (no)
HU (1) HUE038529T2 (no)
LT (1) LT2933252T (no)
ME (1) ME02104B (no)
MX (1) MX2012000708A (no)
NO (1) NO2933252T3 (no)
NZ (1) NZ597533A (no)
PL (3) PL3363797T3 (no)
PT (3) PT2933252T (no)
RS (2) RS56981B1 (no)
SI (3) SI2454250T1 (no)
SM (1) SMT201500090B (no)
TW (3) TWI625121B (no)
UY (1) UY32786A (no)
WO (1) WO2011008709A1 (no)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590887A (en) 2008-08-04 2012-09-28 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2528441A4 (en) 2010-01-25 2013-07-10 Chdi Foundation Inc CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
CA2802743C (en) * 2010-07-02 2019-05-07 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
CN106518845B (zh) * 2011-08-30 2019-09-13 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2015201188B2 (en) * 2012-01-27 2016-12-15 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitor
UY34573A (es) * 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CA2915250A1 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
US9249151B2 (en) * 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
CN106132403B (zh) 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 喷雾干燥制剂
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CA2931615A1 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US20160331754A1 (en) 2014-01-20 2016-11-17 Gilead Sciences, Inc. Therapies for treating cancers
US20150342943A1 (en) 2014-06-03 2015-12-03 Gilead Sciences, Inc. Methods of treating liver disease
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
TW201618781A (zh) 2014-08-13 2016-06-01 吉李德科學股份有限公司 治療肺高血壓之方法
SG11201701723XA (en) 2014-09-24 2017-04-27 Gilead Sciences Inc Methods of treating liver disease
TWI749934B (zh) * 2014-12-23 2021-12-11 美商基利科學股份有限公司 製備2-氟-4-甲基-5-(4-環丙基-1h-咪唑-1-基)苯甲酸之方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
DK3191470T3 (en) 2015-07-06 2019-04-15 Gilead Sciences Inc COT MODULATORS AND METHODS OF USING THEREOF
KR20180026760A (ko) * 2015-07-09 2018-03-13 얀센 파마슈티카 엔.브이. 치환된 4-아자인돌 및 glun2b 수용체 조절제로서의 이의 용도
KR200483190Y1 (ko) 2015-09-11 2017-04-13 주식회사 엔젤악기 바로크식 운지법과 독일식 운지법의 선택 적용이 가능한 리코더 링
TW201725044A (zh) 2015-10-01 2017-07-16 基利科學股份有限公司 用於治療癌症之btk抑制劑及查核點抑制劑之組合
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
JP7148401B2 (ja) 2015-11-19 2022-10-05 インサイト・コーポレイション 免疫調節剤としての複素環化合物
CN108700498B (zh) 2015-12-08 2021-07-13 生物马特里卡公司 降低红细胞沉降速率
TW201726623A (zh) * 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
WO2017157885A1 (de) 2016-03-16 2017-09-21 Bayer Cropscience Aktiengesellschaft N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
UA126905C2 (uk) 2016-06-13 2023-02-22 Ай-Маб Байофарма Юес Лімітед Антитіло до pd-l1 та його застосування
MX2018016273A (es) 2016-06-20 2019-07-04 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3032813A1 (en) 2016-08-04 2018-02-08 Gilead Sciences, Inc. Cobicistat for use in cancer treatments
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
JP2019533706A (ja) * 2016-11-11 2019-11-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
CN110036005B (zh) * 2016-11-16 2022-09-27 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
US20180141939A1 (en) 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
US10975055B2 (en) * 2016-11-22 2021-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corp derivados de benzo-oxazol como imunomoduladores
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060233T2 (hu) 2016-12-22 2023-02-28 Incyte Corp Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek
SG11201906579UA (en) * 2017-01-22 2019-08-27 Fujian Cosunter Pharmaceutical Co Ltd Pyridine derivative as ask1 inhibitor and preparation method and use thereof
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
EP4050030A1 (en) 2017-01-24 2022-08-31 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
US11168095B2 (en) 2017-02-07 2021-11-09 Biogen Ma Inc. ASK1 inhibiting agents
CA3054403A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018156901A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
WO2018157277A1 (en) * 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
JP7211959B2 (ja) * 2017-03-03 2023-01-24 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 アミド類誘導体阻害剤及びその製造方法と使用
JOP20180017A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc مثبط كيناز منظم لإشارة تلاشي خلايا
EP3601250A4 (en) 2017-03-27 2020-11-25 Pharmakea, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS
CN110475556A (zh) 2017-03-28 2019-11-19 吉利德科学公司 治疗肝疾病的方法
JOP20190221A1 (ar) * 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
KR20190132515A (ko) 2017-04-12 2019-11-27 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하는 방법
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US10683279B2 (en) 2017-05-12 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10253018B2 (en) 2017-05-25 2019-04-09 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) * 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018233553A1 (zh) * 2017-06-19 2018-12-27 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
CN109265443B (zh) * 2017-07-18 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
WO2019034096A1 (en) * 2017-08-17 2019-02-21 Sunshine Lake Pharma Co., Ltd. FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109456308B (zh) * 2017-09-06 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
JP2020533335A (ja) * 2017-09-08 2020-11-19 フロンセラ ユー．エス． ファーマシューティカルズ エルエルシー アポトーシスシグナル調節キナーゼ阻害剤およびその使用
CN109232538B (zh) * 2017-10-12 2020-07-24 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
CN107793400B (zh) * 2017-10-31 2020-01-31 武汉九州钰民医药科技有限公司 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用
JP7271540B2 (ja) * 2017-11-17 2023-05-11 へパジーン セラピューティクス （エイチケイ） リミテッド Ａｓｋ１阻害剤としての尿素誘導体
CN109956928B (zh) * 2017-12-14 2021-07-09 四川科伦博泰生物医药股份有限公司 吡啶类化合物、其制备方法及用途
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
CN111801314B (zh) * 2018-01-02 2023-10-31 西尔洛克治疗公司 Ask1抑制剂化合物及其用途
CN111655678B (zh) * 2018-01-05 2023-08-22 广州市恒诺康医药科技有限公司 细胞凋亡信号调节激酶-1抑制剂及其应用
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN110294742B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 并环类ask1抑制剂及其应用
CN110294746B (zh) * 2018-03-21 2023-01-31 山东轩竹医药科技有限公司 一种新的ask1抑制剂及其应用
SI3774791T1 (sl) 2018-03-30 2023-04-28 Incyte Corporation Heterociklične spojine kot imunomodulatorji
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
TW202012414A (zh) 2018-04-12 2020-04-01 美商拓臻股份有限公司 三環ask1抑制劑
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
MX2020011225A (es) * 2018-05-02 2021-01-20 Enanta Pharm Inc Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos.
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
CA3098873A1 (en) 2018-05-11 2019-11-14 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
WO2019222112A1 (en) 2018-05-14 2019-11-21 Gilead Sciences, Inc. Mcl-1 inhibitors
SG11202012784SA (en) * 2018-06-27 2021-01-28 Biogen Ma Inc Ask1 inhibiting agents
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP7096460B2 (ja) * 2018-07-20 2022-07-06 福建▲広▼生中霖生物科技有限公司 Ａｓｋ１阻害剤としての結晶形、その製造方法及び利用
CN110818683B (zh) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-吡啶取代脲结构小分子化合物及其合成和应用
CN111107848B (zh) * 2018-08-10 2023-05-23 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
EP3837251B1 (en) * 2018-08-14 2023-06-21 Biogen MA Inc. Ask1 inhibiting agents
WO2020034988A1 (zh) * 2018-08-14 2020-02-20 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
ES2945183T3 (es) * 2018-08-14 2023-06-29 Biogen Ma Inc Compuestos macrocíclicos de piridina como agentes inhibidores de ASK1
WO2020041417A1 (en) * 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US20210213006A1 (en) * 2018-08-29 2021-07-15 Seal Rock Therapeutics, Inc. Methods of treating neurodegenerative diseases
WO2020063727A1 (zh) * 2018-09-30 2020-04-02 山东轩竹医药科技有限公司 三并环类ask1抑制剂及其应用
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
WO2020106707A1 (en) * 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109608441A (zh) * 2018-12-26 2019-04-12 都创(上海)医药科技有限公司 一种ask1抑制剂的合成工艺
CR20210385A (es) 2019-01-15 2021-09-14 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA3129949A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP2022524398A (ja) 2019-03-11 2022-05-02 ギリアード サイエンシーズ， インコーポレイテッド 化合物の製剤およびそれらの使用
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
JP2022544189A (ja) 2019-08-09 2022-10-17 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
KR20220085796A (ko) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN111018831B (zh) * 2019-11-21 2022-05-31 中国药科大学 细胞凋亡信号调节激酶抑制剂及其应用
WO2021133948A1 (en) 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
TWI778562B (zh) 2020-04-02 2022-09-21 美商基利科學股份有限公司 製備cot抑制劑化合物的方法
US20230039553A1 (en) 2020-05-01 2023-02-09 Gilead Sciences, Inc. Cd73 compounds
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用
AR124001A1 (es) 2020-11-06 2023-02-01 Incyte Corp Proceso para fabricar un inhibidor pd-1 / pd-l1 y sales y formas cristalinas del mismo
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
CN117120429A (zh) 2021-03-29 2023-11-24 吉利德科学公司 Khk抑制剂
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022273702A1 (en) 2021-05-13 2023-11-02 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20230046340A1 (en) 2021-06-23 2023-02-16 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CA1121825A (en) 1978-04-11 1982-04-13 Franco Bolasco 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6159731A (en) 1997-02-12 2000-12-12 Massachusetts Institute Of Technology Daxx, a Fas-binding protein that activates JNK and apoptosis
AUPP285898A0 (en) * 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
SI1144600T1 (sl) 1999-03-19 2008-12-31 Aventis Pharma Inc AKT-3-nukleinske kisline, polipeptidi in njihove uporabe
WO2001068585A1 (fr) * 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amides
WO2002038179A1 (fr) * 2000-11-10 2002-05-16 Kissei Pharmaceutical Co., Ltd. Preventifs ou remedes de maladies du reticulum endoblastique liees au stress
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
JPWO2005009470A1 (ja) 2003-07-28 2006-09-28 財団法人大阪産業振興機構 Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
CA2581375A1 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
TW200628159A (en) * 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
JP2008524233A (ja) * 2004-12-16 2008-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 炎症性疾患、増殖性疾患および免疫介在性疾患の治療のためのｔｅｃファミリータンパク質キナーゼのインヒビターとして有用なピリド−２−オン
EP1677113A1 (en) 2004-12-29 2006-07-05 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Method for the identification of protein-protein interactions in disease related protein networks
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
US20080021026A1 (en) 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
WO2008016131A1 (fr) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cycles fusionnés
WO2008042867A2 (en) 2006-09-29 2008-04-10 Emiliem Inc. Modulators of multiple kinases
CA2671194A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP2271646A1 (en) 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8178555B2 (en) 2008-06-24 2012-05-15 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US20110263441A1 (en) 2008-10-15 2011-10-27 Golub Todd R Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US20110294693A1 (en) 2008-11-17 2011-12-01 The George Washington University Compositions and Methods for Identifying Autism Spectrum Disorders
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CA2787360C (en) 2010-02-03 2019-03-05 Takeda Pharmaceutical Company Limited Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
KR20180032686A (ko) 2010-03-24 2018-03-30 아미텍 테러퓨틱 솔루션즈 인크 인산화효소 억제에 유용한 헤테로환 화합물
CA2802743C (en) 2010-07-02 2019-05-07 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
TW201300380A (zh) 2010-10-19 2013-01-01 Comentis Inc 抑制β－分泌酶活性之噁二唑化合物及其使用方法
US20130236441A1 (en) 2010-11-18 2013-09-12 University Of Delaware Methods of treating and preventing thrombotic diseases using ask1 inhibitors
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
EP2678448A4 (en) 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
EP2718721A4 (en) 2011-06-07 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS FOR CANCER
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
RS57157B1 (sr) 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
AU2014366235B2 (en) 2013-12-20 2017-04-13 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
CN103896990B (zh) 2014-03-12 2017-02-08 石家庄诚志永华显示材料有限公司 有机电致发光材料及其应用
US20150342943A1 (en) 2014-06-03 2015-12-03 Gilead Sciences, Inc. Methods of treating liver disease
SG11201701723XA (en) * 2014-09-24 2017-04-27 Gilead Sciences Inc Methods of treating liver disease
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TWI749934B (zh) 2014-12-23 2021-12-11 美商基利科學股份有限公司 製備2-氟-4-甲基-5-(4-環丙基-1h-咪唑-1-基)苯甲酸之方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
US20180021341A1 (en) 2015-01-09 2018-01-25 Gilead Apollo, Llc Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP2019533706A (ja) 2016-11-11 2019-11-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
JOP20180017A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc مثبط كيناز منظم لإشارة تلاشي خلايا
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
CN110475556A (zh) 2017-03-28 2019-11-19 吉利德科学公司 治疗肝疾病的方法
KR20190132515A (ko) 2017-04-12 2019-11-27 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하는 방법
CN111182904A (zh) 2017-10-06 2020-05-19 吉利德科学公司 包含acc抑制剂的组合治疗

Also Published As

Publication number Publication date
CA2767894C (en) 2015-09-15
KR101755524B1 (ko) 2017-08-02
DK2454250T3 (en) 2015-04-20
BR112012000894A2 (pt) 2016-02-23
US20110009410A1 (en) 2011-01-13
PL2933252T3 (pl) 2018-06-29
EP2933252B1 (en) 2018-01-03
US8552196B2 (en) 2013-10-08
JP5745721B2 (ja) 2015-07-08
CY1119889T1 (el) 2018-06-27
WO2011008709A1 (en) 2011-01-20
AU2010273597B2 (en) 2015-07-09
PT2933252T (pt) 2018-03-15
EP3363797A1 (en) 2018-08-22
US20170196844A1 (en) 2017-07-13
US20130035339A1 (en) 2013-02-07
TW201737914A (zh) 2017-11-01
US20160130251A1 (en) 2016-05-12
CA2767894A1 (en) 2011-01-20
EP2933252A1 (en) 2015-10-21
KR20180077338A (ko) 2018-07-06
PL2454250T3 (pl) 2015-08-31
KR20120034735A (ko) 2012-04-12
RS53951B1 (en) 2015-08-31
TW201604189A (zh) 2016-02-01
CN102482257B (zh) 2016-01-20
JP2018184464A (ja) 2018-11-22
ES2662397T3 (es) 2018-04-06
AU2010273597A1 (en) 2012-02-02
TWI491606B (zh) 2015-07-11
EP2454250A1 (en) 2012-05-23
US9586932B2 (en) 2017-03-07
UY32786A (es) 2011-02-28
ES2854710T3 (es) 2021-09-22
US8598360B2 (en) 2013-12-03
HK1170482A1 (en) 2013-03-01
LT2933252T (lt) 2018-03-12
PL3363797T3 (pl) 2021-06-28
US9067933B2 (en) 2015-06-30
CN102482257A (zh) 2012-05-30
ES2854710T8 (es) 2022-02-11
ME02104B (me) 2016-06-20
JP2012532931A (ja) 2012-12-20
EP2454250B1 (en) 2015-01-14
HRP20180413T1 (hr) 2018-04-20
SMT201500090B (it) 2015-05-05
US20130012521A1 (en) 2013-01-10
RS56981B1 (sr) 2018-05-31
HRP20150185T1 (hr) 2015-04-10
DK2933252T3 (en) 2018-04-16
SI2933252T1 (en) 2018-02-28
PT3363797T (pt) 2021-02-23
KR20170081722A (ko) 2017-07-12
US20140018370A1 (en) 2014-01-16
EP3363797B8 (en) 2021-03-10
TWI598347B (zh) 2017-09-11
PT2454250E (pt) 2015-04-09
USRE48711E1 (en) 2021-08-31
TWI625121B (zh) 2018-06-01
HK1216426A1 (zh) 2016-11-11
NZ597533A (en) 2014-03-28
US8378108B2 (en) 2013-02-19
EP3363797A8 (en) 2021-04-28
JP2017071647A (ja) 2017-04-13
TW201113271A (en) 2011-04-16
AR077564A1 (es) 2011-09-07
ES2533796T3 (es) 2015-04-14
HUE038529T2 (hu) 2018-10-29
EP3363797B1 (en) 2020-12-02
JP2015098500A (ja) 2015-05-28
SI3363797T1 (sl) 2021-03-31
MX2012000708A (es) 2012-03-21
EP3858824A1 (en) 2021-08-04
SI2454250T1 (sl) 2015-04-30

Similar Documents

Publication Publication Date Title
BR112012012396A2 (no)
BR112012008267A2 (no)
BR112012008195A2 (no)
NO2933252T3 (no)
BR112012000607A2 (no)
BRPI0924307A2 (no)
BR112012003080A2 (no)
BR122021004633A2 (no)
BR122017024704A2 (no)
BR112012012487A2 (no)
BR112012003853A2 (no)
BR112012009797A2 (no)
BR112012012080A2 (no)
BR112012009446A2 (no)
BR112012009703A2 (no)
BR112012010357A2 (no)
BR112012007656A2 (no)
BR122019005883A2 (no)
BR112012002627A2 (no)
BR112012001263A2 (no)
BR112012000159A2 (no)
BR112012014856A2 (no)
BRPI0924534A2 (no)
BR112012007672A2 (no)
BR112012005951A2 (no)